Search

Objective: To investigate the potential value of PDT(photodynamic therapy) in the treatment of rectal cancer by reviewing the diagnosis and treatment process of a patient with advanced rectal cancer who lost the opportunity of surgery. Methods: Select the case data of a patient receiving photodynamic therapy in our hospital, and analyze the photodynamic mechanism, safety and efficiency, and discuss the efficacy of photodynamic therapy. Results: After the patient received photodynamic therapy, re-examination of the endoscopy showed that the intestinal cavity was smoother than before, the bowel was difficult, and the symptoms of blood in the stool improved. Conclusion: Photodynamic therapy can be used as a radical or palliative treatment for clinical tumor treatment. Because of its advantages of minimally invasive, tissue-specific, repetitive and synergistic radiotherapy and chemotherapy, it plays an important role in early or middle-advanced colorectal cancer and is worthy of clinical promotion.

Background: Esophageal carcinoma (EC) is one of the worst malignant digestive neoplasms with a strong tendency of invasion and metastasis. Despite the improvement of diagnostic and therapeutic methods in the past decades, the prognosis of EC remains unsatisfactory. Xiaoaiping injection (XAPI), a famous traditional Chinese herbal medicine, has been widely applied as a promising adjunctive drug for EC. However, the exact effects and safety of XAPI have yet to be systematically investigated. We aimed to summarize the efficacy and safety of XAPI for the treatment of advanced EC through the meta-analysis, in order to provide scientific reference for the design of future clinical trials. Methods: Relevant randomized controlled trials (RCTs) were searched from Cochrane Library, PubMed, Google Scholar, Web of Science, Excerpt Medica Database, Medline, China National Knowledge Infrastructure, Chinese Biomedical Literature Database, China Scientific Journal Database and Wanfang Database. Papers in English or Chinese published from January 2000 to May 2020 will be included without any restrictions. Study selection and data extraction will be performed independently by 2 investigators. The clinical outcomes including overall response rate, complete response rate, overall survival, Disease-free survival, quality of life, immune function and adverse events, were systematically evaluated. Review Manager 5.3 and Stata 14.0 were used for data analysis, and the quality of the studies was also evaluated. Results: The results of this study will be published in a peer-reviewed journal, and provide more evidence-based guidance in clinical practice. Conclusion: Our study will draw an objective conclusion of the effects of XAPI combined with conventional treatment for advanced EC and provide a helpful evidence for clinicians to formulate the best postoperative adjuvant treatment strategy for EC patients. INPLASY registration number: INPLASY202050094.